N/A N=10 Treatment

Effectiveness of rTMS on Pain and Quality of Life in Patients With Cancer Neuropathic Pain. Clinical Trial.

Neuropathic Pain

Bottom Line

View on ClinicalTrials.gov: NCT05480410 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2025

Primary outcome: Primary: Effect of Change of 20 rTMS Sessions on Pain — 5.53; 1.60; 1.97; 3.48 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Repetitive transcranial magnetic stimulation (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Fundacion Universitaria Maria Cano
Primary completion: Jan 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Effect of Change of 20 rTMS Sessions on Pain	5.53; 1.60; 1.97; 3.48	—
PRIMARY Effect of Change of 20 rTMS Sessions on Pain and Functionality	5.53; 1.60; 1.97; 3.48; 5.75; 0.73	—
SECONDARY Effect of Change of 20 rTMS Sessions on Quality of Life	68.90; 91.00; 85.10; 79.50	—

Summary

The purpose of this study is to evaluate the effectiveness of Repetitive transcranial magnetic stimulation (rTMS) on pain and quality of life in patients with cancer neuropathic pain. Although there are currently different therapeutic options for neuropathic pain, most are limited or restricted to pharmacotherapy. Transcranial magnetic stimulation (TMS) is a tool recently incorporated into neuroscience in the management of neuropathic cancer pain. The study will include 10 patients with oncologic neuropathic pain who will receive 20 sessions of rTMS and the effect on pain and quality of life.

Eligibility Criteria

Inclusion Criteria

Patients with neuropathic pain of oncological origin
Patients of legal age (18 years old)
Patients using their cognitive faculties

Exclusion Criteria

Pregnancy
History of negative reaction to TMS
History of seizure, history of epilepsy stroke, brain surgery and cranial metal implants.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05480410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.